HeartFlow

HeartFlow FFRCT Webinar

The Importance of Lesion-specific FFRCT Values in the Non-invasive Assessment of CAD: A Case-based Discussion

Lesion-specific physiology matters! Three leading experts review cases that demonstrate why and how lesion-specific physiology can inform treatment for patients with CAD and lessons learned from 10 years of FFRCT interpretation.

coronary_artery_disease_in_women_utilizing_ccta_to_make_an_accurate_diagnosis.png

Coronary Artery Disease in Women: Utilizing CCTA to Make an Accurate Diagnosis

We need to change the conversation on women, chest pain and coronary artery disease (CAD). Two leading experts will review women’s unique biology, risk factors, and presenting symptoms of heart disease during this webinar. They also will discuss better ways to detect and diagnose CAD, and how cardiac CT and FFRCT can identify those at-risk and in need of treatment. Join us to learn how cardiovascular (CV) teams can identify women at risk of CAD who are most likely to benefit from further testing and treatment.

Transformational Data and New Paradigms: Evaluating Stable Chest Pain with CCTA

Transformational Data and New Paradigms: Evaluating Stable Chest Pain with CCTA

For over two decades, the World Heart Federation has been leading the World Heart Day movement—informing people around the world that cardiovascular disease (CVD), including heart disease and stroke, is the leading cause of death globally

Heartflow SMART-CT Video

A Study to Measure the Ability of AI-CSQ to SuppoRt The Busy CCTA Reader (SMART-CT)

Michael Morris, MD, director of Cardiac MR and Cardiac CT at Banner Health and Wesley O'Neal, MD, director of cardiac CT and nuclear cardiology at Cone Health, discuss the results of SMART-CT Study.

Insights from the PRECISE Trial 1-Year Data: Optimizing CAD Assessment for Improved Outcomes

Join us for an expert panel webinar on the just-released PRECISE Trial 1-year results that showed using coronary CTA with FFRCT Analysis to evaluate suspected coronary artery disease offers more accurate non-invasive diagnosis, fewer unnecessary tests and higher confidence among physicians in identifying patients needing treatment. The data demonstrates AHA/ACC Chest Pain Guideline-directed CCTA plus FFRCT Precision Pathway is superior to traditional testing. Sign up for the November 15th webinar now!